About Hibiskus Biopharma

About company

Hibiskus Biopharma is an early-stage pharmaceutical venture pursuing the development of small-molecule cancer therapy, TIR-199. TIR-199 is a potent proteasome inhibitor from the syrbactin natural product family. It was discovered by the company’s founders, Profs. Pirrung and Bachmann of the University of California, Riverside (UCR), and Michigan State University (MSU), respectively. UCR holds multiple patents related to the production of TIR-199 and its use in treating cancers and immune disorders.